Patent · US Active

Solid pharmaceutical composition comprising TLR7 agonist

US12357637B2 · kind B2 · utility

0Cited by

1References

15Claims

0Family size

Assignee

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

Jianghui Jing · Lianyungang, CN
Lihui Dong · Lianyungang, CN
Yi Xu · Lianyungang, CN
Xinlu Li · Lianyungang, CN
Xifeng Lu · Lianyungang, CN
Shang Wang · Lianyungang, CN
Haishan Zang · Lianyungang, CN
Min Li · New Orleans, US
Zhilin Chen · Lianyungang, CN
Xiandong Zhao · Lianyungang, CN
Peng Sun · Beijing, CN

Key dates

Filing date	Apr 23, 2020
Grant date	Jul 15, 2025
Priority date	—
Expiry date	Aug 6, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2095
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.